Klin Onkol 2005; 18(2): 55-58.
Summary:
Backgrounds: Multiple myeloma is a hematological disease caused by clonal proliferation of a malignant plasma cell clone. Its incidence is 4 in 100 000. Median survival is 4-5 years. Besides standard therapy including high-dose chemotherapy new approaches such as immunotherapy are taking place.
Design and subjects: Identification of myelomaspecific T cells from healthy blood donors has been tested in an in vitro study based on T cell activation, separation and expansion. Methods and results: Myeloma cell line ARH 77 has been irradiated and used as apoptotic bodies to stimulate allogeneic mononuclear cells from peripheral blood. Activated myeloma-specific T cells produce interferon gamma, can be captured by immunomagnetic beads and further expanded in vitro up to 400x106 T cells within 4 weeks.
Conclusion: This study demonstrates feasibility of identification and separation of tumor-specific T cells that can be expanded in vitro to numbers used in clinical application.
